NJ A4190

Requires practitioners to conduct baseline urine drug testing for new chronic pain patients and random urine screens at least once every 12 months for patients receiving ongoing opioid prescriptions

Mandates practitioners advise patients (or parents/guardians for minors) about the availability of opioid antidotes when prescribing controlled substances for chronic pain

Requires referral to pain management or addiction specialists when treatment objectives are not being met for chronic pain patients on opioids

Amends the definition of "chronic pain" to mean pain persisting for three or more consecutive months that continues after reasonable medical efforts to relieve it

Authorizes practitioners to prescribe up to a 90-day supply via implantable infusion pumps for patients with cancer, intractable pain, or terminal illness